Open AccessThe neonatal Fc receptor in cancer FcRn in cancer
Author(s) -
Cadena Castaneda Diana,
Brachet Guillaume,
Goupille Caroline,
Ouldamer Lobna,
GouilleuxGruart Valérie
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3067
Subject(s) - immunosurveillance , neonatal fc receptor , immune system , cancer , antibody , cancer research , colorectal cancer , immunology , cytotoxic t cell , population , receptor , biology , cancer cell , medicine , immunoglobulin g , in vitro , biochemistry , environmental health
ABSTRACT Since the neonatal IgG Fc receptor (FcRn) was discovered, it was found to be involved in immunoglobulin recycling and biodistribution, immune complexes routing, antigen presentation, humoral immune response, and cancer immunosurveillance. The latest data show that FcRn plays a part in cancer pathophysiology. In various types of cancers, such as lung and colorectal cancer, FcRn has been described as an early marker for prognosis. Dysregulation of FcRn expression by cancer cells allows them to increase their metabolism, and this process could be exploited for passive targeting of cytotoxic drugs. However, the roles of this receptor depend on whether the studied cell population is the tumor tissue or the infiltrating cells, bringing forward the need for further studies.